Apitegromab (SRK-015) — Research Compounds Library | RetatrutideCompare

Selective inhibitor of latent (pro- and pro-/latent) myostatin developed by Scholar Rock for spinal muscular atrophy. Phase 2 TOPAZ trial showed motor-function gains; phase 3 SAPPHIRE completed in 2024.